Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Short-term Investments (2022 - 2025)

Historic Short-term Investments for BioRestorative Therapies (BRTX) over the last 4 years, with Q3 2025 value amounting to $3.9 million.

  • BioRestorative Therapies' Short-term Investments fell 6648.35% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 6648.35%. This contributed to the annual value of $10.2 million for FY2024, which is 3.03% up from last year.
  • Per BioRestorative Therapies' latest filing, its Short-term Investments stood at $3.9 million for Q3 2025, which was down 6648.35% from $5.8 million recorded in Q2 2025.
  • BioRestorative Therapies' 5-year Short-term Investments high stood at $15.3 million for Q1 2024, and its period low was $3.9 million during Q3 2025.
  • Over the past 4 years, BioRestorative Therapies' median Short-term Investments value was $10.2 million (recorded in 2023), while the average stood at $10.0 million.
  • As far as peak fluctuations go, BioRestorative Therapies' Short-term Investments skyrocketed by 4482.66% in 2024, and later tumbled by 6648.35% in 2025.
  • Quarter analysis of 4 years shows BioRestorative Therapies' Short-term Investments stood at $13.0 million in 2022, then fell by 21.89% to $10.2 million in 2023, then rose by 0.03% to $10.2 million in 2024, then tumbled by 61.83% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $5.8 million for Q2 2025, and $7.9 million during Q1 2025.